Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) mTOR Inhibitors Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global mTOR Inhibitors Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Rapamune
      • 1.3.3 Torisel
      • 1.3.4 Afinitor
      • 1.3.5 Zortress
    • 1.4 Market Segment by Application
      • 1.4.1 Global mTOR Inhibitors Market Share by Application (2019-2025)
      • 1.4.2 Tumor Treatment
      • 1.4.3 Kidney Transplant
      • 1.4.4 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global mTOR Inhibitors Market Size
      • 2.1.1 Global mTOR Inhibitors Revenue 2014-2025
      • 2.1.2 Global mTOR Inhibitors Sales 2014-2025
    • 2.2 mTOR Inhibitors Growth Rate by Regions
      • 2.2.1 Global mTOR Inhibitors Sales by Regions 2014-2019
      • 2.2.2 Global mTOR Inhibitors Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 mTOR Inhibitors Sales by Manufacturers
      • 3.1.1 mTOR Inhibitors Sales by Manufacturers 2014-2019
      • 3.1.2 mTOR Inhibitors Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 mTOR Inhibitors Revenue by Manufacturers (2014-2019)
      • 3.2.2 mTOR Inhibitors Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global mTOR Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.3 mTOR Inhibitors Price by Manufacturers
    • 3.4 Key Manufacturers mTOR Inhibitors Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into mTOR Inhibitors Market
    • 3.6 Key Manufacturers mTOR Inhibitors Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Rapamune Sales and Revenue (2014-2019)
      • 4.1.2 Torisel Sales and Revenue (2014-2019)
      • 4.1.3 Afinitor Sales and Revenue (2014-2019)
      • 4.1.4 Zortress Sales and Revenue (2014-2019)
    • 4.2 Global mTOR Inhibitors Sales Market Share by Type
    • 4.3 Global mTOR Inhibitors Revenue Market Share by Type
    • 4.4 mTOR Inhibitors Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global mTOR Inhibitors Sales by Application

    6 United States

    • 6.1 United States mTOR Inhibitors Breakdown Data by Company
    • 6.2 United States mTOR Inhibitors Breakdown Data by Type
    • 6.3 United States mTOR Inhibitors Breakdown Data by Application

    7 European Union

    • 7.1 European Union mTOR Inhibitors Breakdown Data by Company
    • 7.2 European Union mTOR Inhibitors Breakdown Data by Type
    • 7.3 European Union mTOR Inhibitors Breakdown Data by Application

    8 China

    • 8.1 China mTOR Inhibitors Breakdown Data by Company
    • 8.2 China mTOR Inhibitors Breakdown Data by Type
    • 8.3 China mTOR Inhibitors Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World mTOR Inhibitors Breakdown Data by Company
    • 9.2 Rest of World mTOR Inhibitors Breakdown Data by Type
    • 9.3 Rest of World mTOR Inhibitors Breakdown Data by Application
    • 9.4 Rest of World mTOR Inhibitors Breakdown Data by Countries
      • 9.4.1 Rest of World mTOR Inhibitors Sales by Countries
      • 9.4.2 Rest of World mTOR Inhibitors Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 LC Laboratories
      • 10.1.1 LC Laboratories Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of mTOR Inhibitors
      • 10.1.4 mTOR Inhibitors Product Introduction
      • 10.1.5 LC Laboratories Recent Development
    • 10.2 Teva Pharmaceutical Industries Ltd.
      • 10.2.1 Teva Pharmaceutical Industries Ltd. Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of mTOR Inhibitors
      • 10.2.4 mTOR Inhibitors Product Introduction
      • 10.2.5 Teva Pharmaceutical Industries Ltd. Recent Development
    • 10.3 Exelixis
      • 10.3.1 Exelixis Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of mTOR Inhibitors
      • 10.3.4 mTOR Inhibitors Product Introduction
      • 10.3.5 Exelixis Recent Development
    • 10.4 Novartis Oncology
      • 10.4.1 Novartis Oncology Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of mTOR Inhibitors
      • 10.4.4 mTOR Inhibitors Product Introduction
      • 10.4.5 Novartis Oncology Recent Development
    • 10.5 Pfizer
      • 10.5.1 Pfizer Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of mTOR Inhibitors
      • 10.5.4 mTOR Inhibitors Product Introduction
      • 10.5.5 Pfizer Recent Development
    • 10.6 GSK
      • 10.6.1 GSK Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of mTOR Inhibitors
      • 10.6.4 mTOR Inhibitors Product Introduction
      • 10.6.5 GSK Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 mTOR Inhibitors Sales Channels
      • 11.2.2 mTOR Inhibitors Distributors
    • 11.3 mTOR Inhibitors Customers

    12 Market Forecast

    • 12.1 Global mTOR Inhibitors Sales and Revenue Forecast 2019-2025
    • 12.2 Global mTOR Inhibitors Sales Forecast by Type
    • 12.3 Global mTOR Inhibitors Sales Forecast by Application
    • 12.4 mTOR Inhibitors Forecast by Regions
      • 12.4.1 Global mTOR Inhibitors Sales Forecast by Regions 2019-2025
      • 12.4.2 Global mTOR Inhibitors Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      mTOR inhibitors are a class of drugs that inhibit the mechanistic target of rapamycin (mTOR).
      Mammalian target of rapamycin (mTOR) inhibitors block the activity of the mammalian target of rapamycin. Mammalian target of rapamycin is a protein kinase, which regulates growth factors that stimulate cell growth and angiogenesis. In certain cancers the mTOR pathway is more active.
      In 2019, the market size of mTOR Inhibitors is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for mTOR Inhibitors.

      This report studies the global market size of mTOR Inhibitors, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the mTOR Inhibitors sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      LC Laboratories
      Teva Pharmaceutical Industries Ltd.
      Exelixis
      Novartis Oncology
      Pfizer
      GSK
      ...

      Market Segment by Product Type
      Rapamune
      Torisel
      Afinitor
      Zortress

      Market Segment by Application
      Tumor Treatment
      Kidney Transplant
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the mTOR Inhibitors status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key mTOR Inhibitors manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of mTOR Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now